P-136 Phase I open-label single-arm study of dual targeting BCMA and CD19 FasTCAR-T cells (GC012F) as first-line therapy for transplant-eligible newly diagnosed high-risk multiple myeloma

a very favorable safety profile.These preliminary results emphasize the potential of CAR-T treatment in newly-diagnosed MM pts.Additional studies with larger cohorts and longer follow-ups will further show the significance and benefits of earlier line application of CAR-T therapy for MM pts.